SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (“Catalent”) (NYSE:CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced the pricing of an upsized secondary public offering of 23.7 million shares of its common stock by certain of its stockholders (the “Selling Stockholders”) at a price to the public of $29.50 per share. In addition, the Selling Stockholders have granted the underwriters a 30-day over-allotment option to purchase up to an additional 3.555 million shares of common stock. The offering is expected to close on March 9, 2015, subject to customary closing conditions. Catalent is not selling any stock in this transaction and will not receive any proceeds from the sale of the shares by the Selling Stockholders.
Morgan Stanley, J.P. Morgan, BofA Merrill Lynch, Goldman, Sachs & Co., Jefferies and Deutsche Bank Securities are acting as joint bookrunning managers for the offering. Blackstone Capital Markets, Piper Jaffray, Raymond James, Wells Fargo Securities, William Blair and Evercore ISI are acting as co-managers for the offering.
A registration statement relating to the Catalent shares being sold by the Selling Stockholders was declared effective by the U.S. Securities and Exchange Commission (“SEC”) on March 3, 2015.
This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities described above, nor shall there be any sale of such shares of common stock in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
The offering of the shares of common stock will be made only by means of a prospectus, copies of which may be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department., 180 Varick Street, 2nd Floor, New York, NY 10014; or from J.P. Morgan, Attention: Prospectus Department c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717 or via telephone: +1 (866) 803-9204. The registration statement is available on the SEC’s website at www.sec.gov under the registrant’s name.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. You can identify these forward-looking statements by the use of words such as “outlook,” “believes,” “expects,” “potential,” “continues,” “may,” “will,” “should,” “could,” “seeks,” “projects,” “predicts,” “intends,” “plans,” “estimates,” “anticipates” or the negative version of these words or other comparable words and include all discussions of the contemplated secondary public offering. Such forward-looking statements are subject to various risks and uncertainties, including those risks and uncertainties described under the section entitled “Part I —Item 1A. Risk Factors” of Catalent’s Annual Report on Form 10-K for the fiscal year ended June 30, 2014, filed with the SEC, as such factors may be updated from time to time in Catalent’s periodic filings with the SEC, which are accessible on the SEC’s website at www.sec.gov. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Catalent’s filings with the SEC. Catalent undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.